SI-BONE, Inc. (SIBN) witnessed a remarkable 9.39% surge in its stock price on Tuesday, driven by robust fourth-quarter financial results and a strong outlook for 2025. The medical device company specializing in musculoskeletal disorders of the sacropelvic anatomy reported record fourth-quarter worldwide revenue of $49 million, up 26% year-over-year, driven by strong demand for its innovative product portfolio.
The company achieved a significant milestone by delivering positive adjusted EBITDA of $1.9 million in the fourth quarter, marking its first-ever quarterly profit. For the full year 2024, SI-BONE's adjusted EBITDA loss narrowed by over 70% to $5.1 million, highlighting the scalability of its business model and progress towards generating positive free cash flow.
With new product launches like Granite 9.5 and TNT exceeding adoption expectations and continued momentum in its core SI joint fusion business, SI-BONE is well-positioned for sustained growth. The company guided for 2025 worldwide revenue of $193.5 million to $195.5 million, representing year-over-year growth of approximately 16% to 17%, and expects to achieve positive adjusted EBITDA for the full year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。